Meta-Analysis of Randomized Trials: Efficacy and Safety of Colchicine for Secondary Prevention of Cardiovascular Disease
Journal of Interventional Cardiology · 2024
DOI: 10.1155/2024/8646351 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Journal of Interventional Cardiology, 2024. Verfasst von Elie Akl und 6 weiteren Autor:innen. Beteiligte Einrichtung: McGill University, Montreal, Canada. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Myocardial Infarction, Stroke, Coronary Artery Disease. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Colchicine has shown potential cardioprotective effects owing to its broad anti-inflammatory properties. We performed a meta-analysis to assess its safety and efficacy in secondary prevention in patients with established coronary artery disease (CAD).
Methods
We searched Ovid Healthstar, MEDLINE, and Embase (inception to May 2022) for randomized controlled trials (RCTs) evaluating the cardiovascular effects of colchicine compared with placebo or usual care in patients with CAD. Study-level data on efficacy and safety outcomes were pooled using the Peto method. The primary outcome was the composite of cardiovascular (CV) death, myocardial infarction (MI), or stroke.
Results
A total of 8 RCTs were included with a follow-up duration of ≥1 month, comprising a total of 12,151 patients. Compared with placebo or usual care, colchicine was associated with a significant risk reduction in the primary outcome (odds ratio (OR) 0.70, 95% CI 0.60 to 0.83, P < 0.0001 ; I 2 = 52 % ). Risks of MI (OR 0.75, 95% CI 0.62 to 0.91, P = 0.003 ; I 2 = 33 % ), stroke (OR 0.47, 95% CI 0.30 to 0.74, P = 0.001 ; I 2 = 0 % ), and unplanned coronary revascularization (OR 0.67, 95% CI 0.55 to 0.82, P = 0.0001 ; I 2 = 58 % ) were all reduced in the colchicine group. Rates of CV and all-cause mortality did not differ between the two groups, but there was an increase in noncardiac deaths with colchicine (OR 1.54, 95% CI 1.10 to 2.15, P = 0.01 ; I 2 = 51 % ). The occurrence of all other adverse events was similar between the two groups, including GI reactions (OR 1.06, 95% CI 0.94 to 1.20, P = 0.35 ; I 2 = 42 % ) and infections (OR 1.04, 95% CI 0.84 to 1.28, P = 0.74 ; I 2 = 53 % ).
Conclusions
Colchicine therapy may reduce the risk of future cardiovascular events in patients with established CAD; however, there remains a concern about non-CV mortality. Further trials are underway that will shed light on non-CV mortality and colchicine NCT03048825, and NCT02898610.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- McGill University, Montreal, Canada.
- McMaster University, Hamilton, Canada.
ORCID-Profile: Elie Akl, Ali Zgheib
Zitieren
APA
Akl, E., Sahami, N., Labos, C., Genest, J., Zgheib, A., Piazza, N., & Jolly, S. (2024). Meta-Analysis of Randomized Trials: Efficacy and Safety of Colchicine for Secondary Prevention of Cardiovascular Disease. Journal of Interventional Cardiology. https://doi.org/10.1155/2024/8646351
Vancouver
Akl E, Sahami N, Labos C, Genest J, Zgheib A, Piazza N, et al. Meta-Analysis of Randomized Trials: Efficacy and Safety of Colchicine for Secondary Prevention of Cardiovascular Disease. Journal of Interventional Cardiology. 2024. doi:10.1155/2024/8646351
BibTeX
@article{Akl2024,
author = {Akl, Elie and Sahami, Nazanin and Labos, Christopher and Genest, Jacques and Zgheib, Ali and Piazza, Nicolo and Jolly, Sanjit},
title = {Meta-Analysis of Randomized Trials: Efficacy and Safety of Colchicine for Secondary Prevention of Cardiovascular Disease},
journal = {Journal of Interventional Cardiology},
year = {2024},
doi = {10.1155/2024/8646351}
}
EUVIMED